After 25 years in orthopaedic oncology the author wishes to set a challenge for the next generation by posing 10 questions which he believes still do not have answers and which may improve outcomes for patients with sarcomas Why are sarcomas diagnosed so late? Can we ever decide what is a safe margin? What is the role of neoadjuvant chemotherapy for STS? What can we do to decrease the risk of infection after limb salvage surgery? What is the significance of local recurrence on outcome? What really is the best treatment for Ewing's sarcoma of the pelvis? Is cross sectional imaging essential as part of patient follow up? Is it possible to evaluate outcomes combining survival and function? Why can't we run a surgical trial in orthopaedic oncology? How can we evaluate surgical success? The author suggests ways these questions may be answered.
As tumours of bone and soft tissue are rare, multicentre prospective collaboration is essential for meaningful research and evidence-based advances in patient care. The aim of this study was to identify barriers and facilitators encountered in large-scale collaborative research by orthopaedic oncological surgeons involved or interested in prospective multicentre collaboration. All surgeons who were involved, or had expressed an interest, in the ongoing Prophylactic Antibiotic Regimens in Tumour Surgery (PARITY) trial were invited to participate in a focus group to discuss their experiences with collaborative research in this area. The discussion was digitally recorded, transcribed and anonymised. The transcript was analysed qualitatively, using an analytic approach which aims to organise the data in the language of the participants with little theoretical interpretation.Objectives
Methods
